Human vitreous concentrations of citicoline following topical application of citicoline 2% ophthalmic solution

English version

Autoři: Carmela Carnevale ^aff001; Gianluca Manni ^aff001; Gloria Roberti ^aff001; Alessandra Micera ^aff001; Luca Bruno ^aff001; Andrea Cacciamani ^aff001; Romeo Altafini ^aff003; Luciano Quaranta ^aff004; Luca Agnifili ^aff005; Lucia Tanga ^aff001; Ivano Riva ^aff001; Francesco Oddone ^aff001
Působiště autorů: IRCCS-Fondazione Bietti, Rome, Italy ^aff001; DSCMT, University of Rome Tor Vergata, Rome, Italy ^aff002; Ophthalmology Clinic, Dolo Hospital, Venezia, Italy ^aff003; Department of Surgical & Clinical, Diagnostic and Pediatric Sciences, Section of Ophthalmology, University of Pavia-IRCCS Fondazione Policlinico San Matteo, Pavia, Italy ^aff004; Ophthalmology Clinic, Department of Medicine and Aging Science, University G. d'Annunzio of Chieti-Pescara, Chieti, Italy ^aff005
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pone.0224982

Souhrn

Purpose

To evaluate the presence and concentration of citicoline and its metabolites (choline, cytidine and uridine) in the vitreous body in human eyes after topical application of an ophthalmic solution of citicoline 2%, in vivo.

Methods

Twenty-one subjects affected by epiretinal membrane with surgical indication for pars-plana vitrectomy underwent treatment with 1 drop 3 times/day of a solution of citicoline 2%, 0.2% high molecular weight hyaluronic acid and 0.01% benzalkonium chloride (OMK1, Omikron Italia s.r.l., Rome, Italy) 14 days before surgery and 2 hours prior to surgery. Five additional patients served as controls and received an OMK1 vehicle solution without citicoline. The vitreous samples were taken at the beginning of the pars-plana vitrectomy and analyzed for qualitative/quantitative determination of vitreous concentration of citicoline and its metabolites by means of high performance liquid chromatography.

Results

The overall mean concentration of citicoline in patients treated with citicoline 2% solution was 406.72 ± 52.99 μg/mL, while the mean concentration of choline, cytidine and uridine was 180.88 ± 41.49 μg/mL, 44.45 ± 10.19 μg/mL and 330.41 ± 75.8 μg/mL, respectively. The concentration of citicoline in phakic eyes (n = 13, 366.61 ± 129.61 μg/mL) was lower compared to that found in pseudophakic eyes (n = 8, 435.89 ± 131.42 μg/mL) and the difference was not statistically significant. The concentration of citicoline in the control eyes was 45.66 ± 26.36 μg/mL, while the concentration of choline, cytidine and uridine were 17.21 ± 9.93 μg/mL, 6.24 ± 3.6 μg/mL and 172.80 ± 99.76 μg/mL, respectively.

Conclusion

Citicoline can reach the human vitreous in high concentration when administered in ophthalmic solution. This evidence contributes to the build-up of the pyramid of the evidences required for determining the role of citicoline administered in ophthalmic formulation in retinal and optic nerve neurodegenerative diseases.

Klíčová slova:

High performance liquid chromatography – Surgical and invasive medical procedures – Eyes – Cornea – Cataract surgery – Metabolites – Uridine – Cholines

Zdroje

1. Secades JJ, Lorenzo JL. Citicoline: pharmacological and clinical review, 2006 update. Methods Find Exp Clin Pharmacol. 2006 Sep;28 Suppl B:1–56. 17171187

2. Martinet M, Fonlupt P, Pacheco H. Effects of cytidine-5' diphosphocholine on norepinephrine, dopamine and serotonin synthesis in various regions of the rat brain. Arch Int Pharmacodyn Ther. 1979 May;239(1):52–61. 485720

3. Wang L, Albrecht MA, Wurtman RJ. Dietary supplementation with uridine-5'-monophosphate (UMP), a membrane phosphatide precursor, increases acetylcholine level and release in striatum of aged rat. Brain Res. 2007 Feb 16;1133(1):42–8. doi: 10.1016/j.brainres.2006.11.048 17184749

4. Secades JJ, Alvarez-Sabín J, Castillo J, Díez-Tejedor E, Martínez-Vila E, Ríos J, et al. Citicoline for Acute Ischemic Stroke: A Systematic Review and Formal Meta-analysis of Randomized, Double-Blind, and Placebo-Controlled Trials. J Stroke Cerebrovasc Dis. 2016 Aug;25(8):1984–96. doi: 10.1016/j.jstrokecerebrovasdis.2016.04.010 27234918

5. Gareri P, Castagna A, Cotroneo AM, Putignano D, Conforti R, Santamaria F, et al. The Citicholinage Study: Citicoline Plus Cholinesterase Inhibitors in Aged Patients Affected with Alzheimer's Disease Study. J Alzheimers Dis. 2017;56(2):557–565. doi: 10.3233/JAD-160808 28035929

6. Agnoli A, Ruggieri S, Denaro A, Bruno G. New strategies in the management of Parkinson's disease: a biological approach using a phospholipid precursor (CDP-choline). Neuropsychobiology. 1982;8(6):289–96. doi: 10.1159/000117914 7162583

7. Porciatti V, Schiavi C, Benedetti P, Baldi A, Campos EC. Cytidine-5'-diphosphocholine improves visual acuity, contrast sensitivity and visually-evoked potentials of amblyopic subjects. Curr Eye Res. 1998 Feb;17(2):141–8. doi: 10.1076/ceyr.17.2.141.5606 9523091

8. Fresina M, Dickmann A, Salerni A, De Gregorio F, Campos EC. Effect of oral CDP-choline on visual function in young amblyopic patients. Graefes Arch Clin Exp Ophthalmol. 2008 Jan;246(1):143–50. doi: 10.1007/s00417-007-0621-6 17638004

9. Parisi V, Coppola G, Ziccardi L, Gallinaro G, Falsini B. Cytidine-5'-diphosphocholine (Citicoline): a pilot study in patients with non-arteritic ischaemic optic neuropathy. Eur J Neurol. 2008 May;15(5):465–74. doi: 10.1111/j.1468-1331.2008.02099.x 18325025

10. Parisi V, Barbano L, Di Renzo A, Coppola G, Ziccardi L. Neuroenhancement and neuroprotection by oral solution citicoline in non-arteritic ischemic optic neuropathy as a model of neurodegeneration: A randomized pilot study. PLoS One. 2019 Jul 26;14(7):e0220435. doi: 10.1371/journal.pone.0220435 31348806

11. Grieb P, Jünemann A, Rekas M, Rejdak R. Citicoline: A Food Beneficial for Patients Suffering from or Threated with Glaucoma. Front Aging Neurosci. 2016 Apr 8;8:73. doi: 10.3389/fnagi.2016.00073 27092075

12. Faiq MA, Wollstein G, Schuman JS, Chan KC. Cholinergic nervous system and glaucoma: From basic science to clinical applications. Prog Retin Eye Res. 2019 Sep;72:100767. doi: 10.1016/j.preteyeres.2019.06.003 31242454

13. Roberti G, Tanga L, Parisi V, Sampalmieri M, Centofanti M, Manni G. A preliminary study of the neuroprotective role of citicoline eye drops in glaucomatous optic neuropathy. Indian J Ophthalmol. 2014 May;62(5):549–53. doi: 10.4103/0301-4738.133484 24881599

14. Kaur IP, Smitha R. Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery. Drug Dev Ind Pharm. 2002 Apr;28(4):353–69. doi: 10.1081/ddc-120002997 12056529

15. Roberti G, Tanga L, Michelessi M, Quaranta L, Parisi V, Manni G, et al. Cytidine 5'-Diphosphocholine (Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future Perspectives. Int J Mol Sci. 2015 Nov 30;16(12):28401–17. doi: 10.3390/ijms161226099 26633368

16. Zafonte RD, Bagiella E, Ansel BM, Novack TA, Friedewald WT, Hesdorffer DC, et al. Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT). JAMA. 2012 Nov 21;308(19):1993–2000. doi: 10.1001/jama.2012.13256 23168823

17. Secades JJ. Citicoline: pharmacological and clinical review, 2016 update. Rev Neurol. 2016 Dec 23;63(S03):S1–S73. 28417449

18. Parisi V, Manni G, Colacino G, Bucci MG. Cytidine-5'-diphosphocholine (citicoline) improves retinal and cortical responses in patients with glaucoma. Ophthalmology. 1999 Jun;106(6):1126–34. doi: 10.1016/S0161-6420(99)90269-5 10366081

19. Bogdanov P, Sampedro J, Solà-Adell C, Simó-Servat O, Russo C, Varela-Sende L, et al. Effects of Liposomal Formulation of Citicoline in Experimental Diabetes-Induced Retinal Neurodegeneration. Int J Mol Sci. 2018 Aug 20;19(8).

20. Park CH, Kim YS, Noh HS, Cheon EW, Yang YA, Yoo JM, et al. Neuroprotective effect of citicoline against KA-induced neurotoxicity in the rat retina. Exp Eye Res. 2005 Sep;81(3):350–8. doi: 10.1016/j.exer.2005.02.007 16129102

21. Matteucci A, Varano M, Gaddini L, Mallozzi C, Villa M, Pricci F, et al. Neuroprotective effects of citicoline in in vitro models of retinal neurodegeneration. Int J Mol Sci. 2014 Apr 14;15(4):6286–97. doi: 10.3390/ijms15046286 24736780

22. Rejdak R, Toczolowski J, Solski J, Duma D, Grieb P. Citicoline treatment increases retinal dopamine content in rabbits. Ophthalmic Res. 2002 May-Jun;34(3):146–9. doi: 10.1159/000063658 12097797

23. Parisi V, Coppola G, Centofanti M, Oddone F, Angrisani AM, Ziccardi L, et al. Evidence of the neuroprotective role of citicoline in glaucoma patients. Prog Brain Res. 2008;173:541–54. doi: 10.1016/S0079-6123(08)01137-0 18929133

24. Ottobelli L, Manni GL, Centofanti M, Iester M, Allevena F, Rossetti L. Citicoline oral solution in glaucoma: is there a role in slowing disease progression? Ophthalmologica. 2013;229(4):219–26. doi: 10.1159/000350496 23615390

25. Parisi V, Centofanti M, Ziccardi L, Tanga L, Michelessi M, Roberti G, et al. Treatment with citicoline eye drops enhances retinal function and neural conduction along the visual pathways in open angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 2015 Aug;253(8):1327–40. doi: 10.1007/s00417-015-3044-9 26004075

26. Takamura Y, Tomomatsu T, Matsumura T, Takihara Y, Kozai S, Arimura S, et al. Vitreous and aqueous concentrations of brimonidine following topical application of brimonidine tartrate 0.1% ophthalmic solution in humans. J Ocul Pharmacol Ther. 2015 Jun;31(5):282–5. doi: 10.1089/jop.2015.0003 25918904

27. Kent AR, Nussdorf JD, David R, Tyson F, Small D, Fellows D. Vitreous concentration of topically applied brimonidine tartrate 0.2%. Ophthalmology. 2001 Apr;108(4):784–7. doi: 10.1016/s0161-6420(00)00654-0 11297498

28. Connolly GP, Duley JA. Uridine and its nucleotides: biological actions, therapeutic potentials. Trends Pharmacol Sci. 1999 May;20(5):218–25. doi: 10.1016/s0165-6147(99)01298-5 10354618

29. Martinez-de-la-Casa JM, Rayward O, Saenz-Frances F, Santos-Bueso E, Mendez-Hernandez C, Herrero-Vanrell R, et al. Effects of corneal thickness on the intraocular penetration of travoprost 0.004%. Eye (Lond). 2012 Jul;26(7):972–5.

30. Spierer O, Regenbogen M, Lazar M, Yatziv Y. Effect of Corneal Thickness on the Penetration of Topical Vancomycin. Optom Vis Sci. 2015 Oct;92(10):1027–31. doi: 10.1097/OPX.0000000000000692 26258280